FG-2216

DB08687InvestigationalSmall molecule

A orally active prolyl-hydroxylase inhibitor which can stabilize hypoxia-inducible transcription factor independent of oxygen availability.

Chemical structure of FG-2216
Primary indication
Investigated for use/treatment in anemia and kidney disease.Curator reviewed
Formula / weight
C12H9ClN2O4 · 280.664 g/mol (avg)
Code names
FG-2216

Resolves to

Compound
UNIIRU921DS4Z5CAS223387-75-5ChEMBLCHEMBL426560PubChem6914666
Structure
InChIKeyOUQVKRKGTAUJQA-UHFFFAOYSA-NSMILESOC(=O)CNC(=O)C1=C(O)C2=CC=CC=C2C(Cl)=N1
Targets
Q9GZT9EGLN1Q16665HIF1A

What you can answer from here — as of April 23, 2025

2Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
1Clinical trialPhase, status and sponsor resolved per trial
Sign in
6+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with FG-2216, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In